Scott M. Schuetze,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Funda Meric‐Bernstam,Carmen Calfa,Laura Catherine Farrington,Michael B. Livingston,Kristopher Wentzel,Deepti Behl,Yelena Kier,Alissa Marr,Margaret von Mehren,Joshua Z. Press,Ramya Thota,Gina N. Grantham,Abigail Gregory,Dominique C. Hinshaw,Susan Halabi,Richard L. Schilsky
出处
期刊：JCO precision oncology [American Society of Clinical Oncology] 日期：2024-07-01卷期号： (8)
Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (
cocolu
杳鸢
ceeray23
劲秉
pluto
藤椒辣鱼
彭于彦祖
SYLH
iNk
Yifan2024
tuanheqi
36456657
guo
方羽
坚强亦丝
cctv18
幽壑之潜蛟
无名老大
小菜鸟001
坚强的广山
皖公网安备34019202002308
